首页>投融资
ONL Therapeutics
D轮
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.In March 2023, ONL Therapeutics LLC closed on the first tranche of a $15 million Series C Preferred Stock financing round.In December 2020 ,ONL Therapeutics announced that it closed on $46.9 million in a Series B Preferred Stock financing round. In January 2022, ONL Therapeutics Inc closed on its second tranche of Series B financing raising $46.9 million.In August 2019, the company raised US $3 million in a convertible note financing.In May 2017, the company closed a US $4.25 million Series A round of fundraising
基本信息
-
公司全称ONL Therapeutics Inc
-
类型眼科药物研发商
-
产业领域生物药、药品研发/制造
-
公司人数15~50人
-
地址524 S. Main St,Suite 110 ANN ARBOR MICHIGAN 48104; US; Telephone: +17349988339;
-
联系电话（734）998.8339
-
邮箱info@onltherapeutics.com
-
成立时间2011-01-01
投融资
-
2024-09-13D轮6500万美元Johnson & Johnson InnovationVisionary Venture FundBios Partners诺华
-
2023-03-08C轮1500万美元Bios PartnersVisionary Venture FundAlpine VisionaryMayewell CapitalJohnson & Johnson Innovation凯泰资本PSQ CapitalMichigan CapitalExSight VenturesCapital Community AngelsMINTS
-
2020-12-22B轮4690万美元Capital Community AngelsMichigan CapitalMINTSExSight VenturesInFocus Capital PartnersPSQ Capital凯泰资本强生（中国）Bios Partners
-
2019-08-22债权融资300万美元Invest MichiganCCAIInFocus Capital PartnersBRCC
-
2017-05-17A轮425万美元诺华
-
2017-03-21捐赠/众筹/授予100万美元National Institutes of Health
-
2014-11-12捐赠/众筹/授予137万美元National Eye Institute
- 加载更多
相关投融资企业
D轮
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.In March 2023, ONL Therapeutics LLC closed on the first tranche of a $15 million Series C Preferred Stock financing round.In December 2020 ,ONL Therapeutics announced that it closed on $46.9 million in a Series B Preferred Stock financing round. In January 2022, ONL Therapeutics Inc closed on its second tranche of Series B financing raising $46.9 million.In August 2019, the company raised US $3 million in a convertible note financing.In May 2017, the company closed a US $4.25 million Series A round of fundraising
股权融资
Abata Therapeutics Inc is a biotechnology company focuses on the development of transformational medicine using targeted regulatory T cells (Tregs) for treatment of autoimmune and inflammatory diseases
A轮
浩博医药成立于2019年8月，致力于研发用于治疗和预防慢性乙型肝炎及其他重大传染疾病的创新药物和疫苗。公司创始人和首席执行官（CEO）为程国锋博士。目前，浩博医药的三大创新管线乙肝治愈小核酸药物平台、乙肝治疗性疫苗平台、合作开发的鼻喷抗体平台都已经进入了临床试验申报阶段。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息